Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer
Enfortumab vedotin-related cutaneous toxicity: Clinical features, pathogenesis and management. (PubMed, J Dermatol Sci) - Sep 18, 2026 - "This review summarizes the molecular structure and function of nectin-4 and the clinical and histopathologic features of EV-related cutaneous toxicity and discusses current approaches to management. By integrating mechanistic insights from experimental studies with clinical and histopathologic observations, this review provides a translational framework to support optimal recognition and management of EV-related cutaneous toxicity." 
Journal • Review • Oncology • Solid Tumor • Steven-Johnson Syndrome • Urothelial Cancer • NECTIN4
http://www.ncbi.nlm.nih.gov/pubmed/42754439
 
Kazumasa Oya
 
Sep 18, 2026
 
Prev Next